The concept of repressing APP translation as a therapeutic strategy in DS and AD was proven as a novel anti-amyloid strategy as exemplified by our use of the APP 5′UTR-directed FDA drug N-acetyl-cysteine (NAC) in the TgCRND8 APP(Swe) mouse model of AD [8]. The gene discussed is APP; the disease is Alzheimer disease.